Vaccination against human papilloma virus (HPV), a group of more than 200 viruses infecting at least 50% of sexually active people over their lifetimes, has proven more than 90% effective for ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company’s 9-valent Human ...

Medically reviewed by Lindsay Cook, PharmDMedically reviewed by Lindsay Cook, PharmD Gardasil 9 is a vaccine (immunization) that protects against human papillomavirus (HPV). Gardasil side effects are ...

V503-064 is a Phase 3, double-blind, placebo-controlled clinical study (NCT04635423) to evaluate the safety/tolerability and efficacy of GARDASIL 9 (V503) in preventing HPV-related anogenital ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating ...